AZN.UK

10,146

-0.51%↓

GSK

1,393.5

-0.75%↓

AZN.UK

10,146

-0.51%↓

GSK

1,393.5

-0.75%↓

AZN.UK

10,146

-0.51%↓

GSK

1,393.5

-0.75%↓

AZN.UK

10,146

-0.51%↓

GSK

1,393.5

-0.75%↓

AZN.UK

10,146

-0.51%↓

GSK

1,393.5

-0.75%↓

Search

Indivior PLC

Fermé

1,083 10.23

Résumé

Variation du prix de l'action

24h

Actuel

Min

979

Max

1086

Chiffres clés

By Trading Economics

Revenu

-19M

47M

Ventes

-33M

266M

P/E

Moyenne du Secteur

330

50.291

BPA

0.41

Marge bénéficiaire

17.669

Employés

1,030

EBITDA

-30M

76M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+3.83% upside

Dividendes

By Dow Jones

Prochains Résultats

24 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

504M

1.3B

Ouverture précédente

1072.77

Clôture précédente

1083

Indivior PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 juin 2025, 23:59 UTC

Market Talk

Oil Falls Amid Abating Middle East Tensions -- Market Talk

29 juin 2025, 23:47 UTC

Market Talk

Gold Edges Lower Amid Trade Deal Hopes, Risk Appetite -- Market Talk

29 juin 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

29 juin 2025, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 juin 2025, 22:48 UTC

Market Talk

Export Data Buoy Fisher & Paykel Healthcare Bull -- Market Talk

28 juin 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

28 juin 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:51 UTC

Résultats

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 juin 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 juin 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 juin 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 juin 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 juin 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 juin 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 juin 2025, 18:39 UTC

Market Talk
Résultats

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 juin 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 juin 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 juin 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 juin 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 juin 2025, 17:08 UTC

Résultats

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 juin 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

Comparaison

Variation de prix

Indivior PLC prévision

Objectif de Prix

By TipRanks

3.83% hausse

Prévisions sur 12 Mois

Moyen 1,023.72 GBX  3.83%

Haut 1,100 GBX

Bas 947.447 GBX

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.